文献速递临床免疫临床血液与体液

基于临床病理与血清学参数构建卵巢癌手术结局与预后预测模型

A predictive and prognostic model for surgical outcome and prognosis in ovarian cancer computed by clinico-pathological and serological parameters (CA125, HE4, mesothelin).
PubMed 文献 · Clin Chem Lab Med · 2023-10-11

本研究利用190例卵巢癌患者的342份血清样本,检测CA125、HE4和间皮素,构建预测手术结局与预后的模型。术前HE4联合CA125预测手术结局的AUC为0.86;预后模型整合术前CA125、术后HE4、术后间皮素及手术结局,分层高风险患者复发或死亡预测AUC为0.89,无进展生存和总生存显著缩短。

要点

  • 术前HE4联合CA125是预测手术结局的最佳血清标志物组合,AUC=0.86。
  • 预后模型整合术前CA125、术后HE4、术后间皮素及手术结局,性能优于单一参数。
  • 高风险患者复发或死亡预测AUC=0.89,无进展生存HR=9.74,总生存HR=5.62。

核心结论

  • 基于临床病理因素和CA125、HE4、间皮素构建的预测/预后模型稳健,可常规用于识别高复发风险的卵巢癌患者。

研究设计与样本

  • 回顾性分析190例卵巢癌患者的342份血清样本,其中152份为配对术前和术后样本。
  • 采用Lumipulse® G化学发光酶免疫分析法(Fujirebio)定量血清CA125、HE4和间皮素。

主要发现

  • 术前HE4联合CA125预测手术结局的AUC为0.86。
  • 预后模型整合术前CA125、术后HE4、术后间皮素及手术结局,性能优于任一单一参数,且独立于BRCA1/2突变状态。
  • 高风险患者复发或死亡预测AUC为0.89,无进展生存显著缩短(HR=9.74;95%CI 5.95-15.93;p<0.0001),总生存显著缩短(HR=5.62;95%CI 3.16-9.99;p<0.0001)。

关键数值与推荐

  • 术前HE4联合CA125预测手术结局AUC=0.86。
  • 预后风险指数将患者分为「较低风险」和「较高风险」,高风险患者复发或死亡预测AUC=0.89。
  • 高风险患者无进展生存HR=9.74(95%CI 5.95-15.93;p<0.0001),总生存HR=5.62(95%CI 3.16-9.99;p<0.0001)。

临床怎么用

  • 术前检测HE4和CA125可用于预测卵巢癌手术结局。
  • 术后检测HE4和间皮素联合术前CA125及手术结局可计算预后风险指数,识别高复发风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Numerous prognostic models have been proposed for ovarian cancer, extending from single serological factors to complex gene-expression signatures. Nonetheless, these models have not been routinely translated into clinical practice. We constructed a robust and readily calculable model for predicting surgical outcome and prognosis of ovarian cancer patients by exploiting commonly available clinico-pathological factors and three selected serum parameters. METHODS: Serum CA125, human epididymis protein 4 (HE4) and mesothelin (MSL) were quantified by Lumipulse® G chemiluminescent enzyme immunoassay (Fujirebio) in a total of 342 serum samples from 190 ovarian cancer patients, including 152 paired pre- and post-operative samples. RESULTS: Detection of pre-operative HE4 and CA125 was the optimal marker combination for blood-based prediction of surgical outcome (AUC=0.86). We constructed a prognostic model, computed by serum levels of pre-operative CA125, post-operative HE4, post-operative MSL and surgical outcome. Prognostic performance of our model was superior to any of these parameters alone and was independent from BRCA1/2 mutational status. We subsequently transformed our model into a prognostic risk index, stratifying patients as "lower risk" or "higher risk". In "higher risk" patients, relapse or death was predicted with an AUC of 0.89 and they had a significantly shorter progression free survival (HR: 9.74; 95 % CI: 5.95-15.93; p<0.0001) and overall survival (HR: 5.62; 95 % CI: 3.16-9.99; p<0.0001) compared to "lower risk" patients. CONCLUSIONS: We present a robust predictive/prognostic model for ovarian cancer, which could readily be implemented into routine diagnostics in order to identify ovarian cancer patients at high risk of recurrence.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Klotz DM, Link T, Wimberger P, et al. A predictive and prognostic model for surgical outcome and prognosis in ovarian cancer computed by clinico-pathological and serological parameters (CA125, HE4, mesothelin). Clin Chem Lab Med. 2023. PMID: 37816681. doi:10.1515/cclm-2023-0314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。